WO2014089378A1 - Thienopyridine derivatives for the treatment and prevention of dengue virus infections - Google Patents

Thienopyridine derivatives for the treatment and prevention of dengue virus infections Download PDF

Info

Publication number
WO2014089378A1
WO2014089378A1 PCT/US2013/073449 US2013073449W WO2014089378A1 WO 2014089378 A1 WO2014089378 A1 WO 2014089378A1 US 2013073449 W US2013073449 W US 2013073449W WO 2014089378 A1 WO2014089378 A1 WO 2014089378A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino
thieno
pyridine
carboxamide
phenyl
Prior art date
Application number
PCT/US2013/073449
Other languages
English (en)
French (fr)
Inventor
Dongcheng Dai
James R. Burgeson
Shanthakumar R. Tyavanagimatt
Chelsea M. Byrd
Dennis E. Hruby
Original Assignee
Siga Technologies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/708,224 external-priority patent/US20130129677A1/en
Application filed by Siga Technologies, Inc. filed Critical Siga Technologies, Inc.
Priority to CA2893318A priority Critical patent/CA2893318A1/en
Priority to JP2015545858A priority patent/JP2016501883A/ja
Priority to EP13859644.0A priority patent/EP2928470A4/en
Publication of WO2014089378A1 publication Critical patent/WO2014089378A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention relates to the use of thienopyridine derivatives and analogs, as well as compositions containing the same, for the treatment of viral diseases associated with the flavivirus family such as Dengue fever, Yellow fever, West Nile, St. Louis encephalitis, Hepatitis C, Murray Valley encephalitis, and Japanese encephalitis.
  • Dengue fever is an acute febrile disease caused by one of four closely related virus serotypes (DEN-1, DEN-2, DEN-3, and DEN-4) . Dengue fever is classified based on its clinical characteristics into classical dengue fever, or the more severe forms, dengue hemorrhagic fever syndrome (DHF) , and dengue shock syndrome (DSS) . Recovery from infection from one serotype produces life-long immunity to that particular
  • Dengue is a member of the Flaviviridae family which are enveloped, positive-sense RNA viruses whose human pathogens also include West Nile virus
  • WNV yellow fever virus
  • JEV Japanese encephalitis virus
  • TBEV tick-borne encephalitis virus
  • WHO World Health Organization
  • dengue disease including major epidemics in Cuba and Venezuela, and outbreaks in Texas and Hawaii (4) . Failure to control the mosquito vector and increases in long-distance travel have contributed to the increase and spread of dengue disease.
  • dengue as a viral hemorrhagic fever virus (arthropod-borne, widely spread, and capable of inducing a great amount of
  • Dengue causes several illnesses with increasing severity being determined in part by prior infection with a different serotype of the virus.
  • Classic dengue fever (DF) begins 3-8 days after the bite of an infected mosquito and is characterized by sudden onset of fever, headache, back pain, joint pain, a measles-like rash, and nausea and vomiting (20) .
  • DF is frequently referred to as "breakbone" fever due to these symptoms.
  • the disease usually resolves after two weeks but a prolonged recovery with weakness and depression is common.
  • the more severe form of the disease dengue hemorrhagic fever (DHF) has a similar onset and early phase of illness as dengue fever.
  • DHF dengue hemorrhagic fever
  • DHF dengue shock syndrome
  • DFS dengue shock syndrome
  • hypovolaemic shock resulting from plasma leakage occur and can lead to death in 12-24 hours without plasma replacement (33) .
  • the case fatality rate of DHF/DSS can be as high as 20% without treatment.
  • DHF has become a leading cause of hospitalization and death among children in many countries with an estimated 500,000 cases requiring
  • antibody-dependent enhancement (8).
  • ADE antibody-dependent enhancement
  • cytotoxic lymphocytes which can result in plasma leakage and the hemorrhagic features characteristic of DHF and DSS (20) .
  • This antibody-dependent enhancement of infection is one reason why the development of a successful vaccine has proven to be so difficult.
  • DHF/DSS can occur after primary infection (29), so virus virulence (15) and immune activation are also believed to contribute to the pathogenesis of the disease (25) .
  • Dengue is endemic in more than 100 countries in Africa, the Americas, the Eastern Mediterranean, South-east Asia and the Western Pacific. During epidemics, attack rates can be as high as 80-90% of the susceptible population. All four serotypes of the virus are emerging worldwide, increasing the number of cases of the disease as well as the number of explosive outbreaks. In 2002 for example, there were 1,015,420 reported cases of dengue in the Americas alone with 14,374 cases of DHF, which is more than three times the number of dengue cases reported in the Americas in 1995 (23) .
  • the dengue genome approximately 11 kb in length, consists of a linear, single stranded, infectious, positive sense RNA that is translated as a single long polyprotein
  • the nonstructural proteins are involved in viral RNA replication (31), viral assembly, and the inflammatory components of the disease (18) .
  • the structural proteins are involved mainly in viral particle formation (21) .
  • the precursor polyprotein is cleaved by cellular proteinases to separate the structural proteins (17), while a virus-encoded proteinase cleaves the nonstructural region of the polyprotein (6) .
  • the genome is capped and does not have a poly (A) tail at the 3' end but instead has a stable stem-loop structure necessary for stability and replication of the genomic RNA (3) .
  • the virus binds to cellular receptors via the E protein and undergoes receptor- mediated endocytosis followed by low-pH fusion in lysosomes (19) .
  • the viral genome is then uncoated and translated into the viral precursor polyprotein.
  • proteolytic processing separates the structural and
  • RNA-dependent RNA polymerase along with cofactors synthesizes the minus-strand RNA which serves as a template for the synthesis of the progeny plus-strand RNA (24) .
  • Viral replication is membrane associated (1, 30) .
  • the genome is encapsidated, and the immature virus, surrounded by a lipid envelope buds into the lumen (9) .
  • the envelope proteins become glycosylated and mature viruses are released outside the cell.
  • Essential stages or process during the virus life cycle would be possible targets for inhibition from an antiviral drug and include binding of the virus to the cell through the E protein, uptake of the virus into the cell, the capping mechanism, the viral proteinase, the viral RNA-dependent RNA polymerase, and the viral helicase.
  • Ribavirin a guanosine analogue
  • Ribavirin a guanosine analogue
  • Having an antiviral drug would also aid vaccine development by having a tool at hand to treat complications that may arise due to unequal immune protection against the different serotypes.
  • a successful vaccine could be a critical component of an effective biodefense, the typical delay to onset of immunity, potential side-effects, cost, and logistics associated with large-scale civilian
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the following general Formula I or a
  • X is selected from the groups consisting of 0, S and N-R' , wherein R' is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl , arylalkyl, aryl, heteroaryl, acyl, arylacyl, heteroarylacyl , sulfonyl, aminosulfonyl , substituted aminosulfonyl ,
  • alkoxycarbonyl cycloalkyloxycarbonyl , aryloxycarbonyl ,
  • R is selected from the group consisting of halogen, cyano, isocyano, nitro, amino, alkylamino, dialkylamino,
  • heteroarylamino acylamino, arylacylamino, heteroarylacylamino, alkylsulfonylamino, arylsulfonylamino, hydroxysulfonyl ,
  • aminosulfonyl substituted aminosulfonyl , acyl, arylacyl, heteroarylacyl, carboxy, alkoxycarbonyl, cycloalkyloxycarbonyl, aryloxycarbonyl, aminocarbonyl , and substituted aminocarbonyl , or R and R together with the carbons they are attached to may form a substituted or unsubstituted ring;
  • A, B, D, and E are independently N or C-R 1 , C-R 2 , C-R 3 and C-R 4 , respectively, wherein R 1 , R 2 , R 3 and R 4 are independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl,
  • heterocycloalkyl arylalkyl, aryl, heteroaryl, hydroxy
  • heteroarylacyloxy alkylsulfonyloxy, arylsulfonyloxy, thio, alkylthio, arylthio, amino, alkylamino, dialkylamino,
  • heteroarylamino acylamino, arylacylamino, heteroarylacylamino, alkylsulfonylamino, arylsulfonylamino, acyl, arylacyl,
  • heteroarylacyl alkylsulfinyl , arylsulfinyl , alkylsulfonyl , arylsulfonyl , aminosulfonyl , substituted aminosulfonyl , carboxy, alkoxycarbonyl , cycloalkyloxycarbonyl , aryloxycarbonyl ,
  • composition must be suitable for human or animal administration .
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the following general Formula II or a
  • X is selected from the groups consisting of 0, S or N-R' , wherein R' is selected from the groups consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl , arylalkyl, aryl, heteroaryl, acyl, arylacyl, heteroarylacyl , sulfonyl, aminosulfonyl , substituted aminosulfonyl ,
  • alkoxycarbonyl cycloalkyloxycarbonyl , aryloxycarbonyl ,
  • R 2 is selected from the groups consisting of hydrogen, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, arylalkyl, aryl, heteroaryl, hydroxy, alkyloxy, aryloxy, heteroaryloxy, acyloxy, arylacyloxy, heteroarylacyloxy, alkylsulfonyloxy,
  • arylsulfonyloxy thio, alkylthio, arylthio, amino, alkylamino, dialkylamino, cycloalkylamino, heterocycloalkylamino, arylamino, heteroarylamino, acylamino, arylacylamino, heteroarylacylamino, alkylsulfonylamino, arylsulfonylamino, acyl, arylacyl, amino, alkylamino, dialkylamino, cycloalkylamino, heterocycloalkylamino, arylamino, heteroarylamino, acylamino, arylacylamino, heteroarylacylamino, alkylsulfonylamino, arylsulfonylamino, acyl, arylacyl,
  • heteroarylacyl alkylsulfinyl , arylsulfinyl , alkylsulfonyl , arylsulfonyl , aminosulfonyl , substituted aminosulfonyl , carboxy, alkoxycarbonyl, cycloalkyloxycarbonyl, aryloxycarbonyl,
  • R 5 and R 6 or R 7 together with the nitrogen atoms they are attached to, along with the carbon of G
  • R 5 and R 8 or R 9 together with the nitrogen atoms they are attached to, along with the carbon of G and two carbons of the X-containing 5-membered ring, may form a substituted or unsubstituted ring, which may be fused with an aromatic or aliphatic ring;
  • R 6 , R 7 , R 8 , and R 9 are independently selected from the groups consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, arylalkyl, aryl, heteroaryl, acyl, arylacyl, heteroarylacyl, sulfonyl, aminosulfonyl , substituted
  • R 6 or R' and R 5 together with the nitrogen atoms they are attached to, along with the carbon of G, or R 8 or R 9 and R 5 , together with the nitrogen atoms they are attached to, along with the carbon of G and two carbons of the X-containing 5-membered ring, or R 6 or R 7 and R 8 or R 9 , together with the nitrogen atoms they are attached to, along with the carbon or sulfur of G and two carbons of the X-containing 5-membered ring, or R 6 and R 7 , together with the nitrogen atom they are attached to, or R 8 and R 9 , together with the nitrogen atom they are attached to, may form a substituted or unsubstituted ring, which may be fused with an aromatic or aliphatic ring; and
  • a 7 or 8-membered ring which contains one or more heteroatoms selected from N, 0 and S, or a 4-membered ring which may
  • the ring may be substituted or unsubstituted, or fused with another ring, which may be aromatic or non-aromatic and may include one or more heteroatoms in the ring and may be fused with an aromatic or aliphatic ring.
  • composition must be suitable for human or animal administration.
  • the present invention further provides a
  • composition comprising a pharmaceutically
  • X is selected from the groups consisting of: 0, S and N-R' , wherein R' is selected from the groups consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl , arylalkyl, aryl, heteroaryl, acyl, arylacyl, heteroarylacyl , sulfonyl, aminosulfonyl , substituted aminosulfonyl ,
  • alkoxycarbonyl cycloalkyloxycarbonyl , aryloxycarbonyl ,
  • R is selected from the group consisting of halogen, cyano, isocyano, nitro, amino, alkylamino, dialkylamino,
  • heteroarylamino acylamino, arylacylamino, heteroarylacylamino, alkylsulfonylamino, arylsulfonylamino, hydroxysulfonyl ,
  • aminosulfonyl substituted aminosulfonyl , acyl, arylacyl, heteroarylacyl , carboxy, alkoxycarbonyl, cycloalkyloxycarbonyl, aryloxycarbonyl, aminocarbonyl , and substituted aminocarbonyl;
  • B, D, and E are independently N or C-R 2 , C-R 3 and C-R 4 , respectively, wherein R 2 , R 3 and R 4 are independently selected from the group consisting of hydrogen, substituted or
  • heterocycloalkyl arylalkyl, aryl, heteroaryl, hydroxy
  • heteroarylacyloxy alkylsulfonyloxy, arylsulfonyloxy, thio, alkylthio, arylthio, amino, alkylamino, dialkylamino,
  • heteroarylamino acylamino, arylacylamino, heteroarylacylamino, alkylsulfonylamino, arylsulfonylamino, acyl, arylacyl,
  • heteroarylacyl alkylsulfinyl , arylsulfinyl , alkylsulfonyl , arylsulfonyl , aminosulfonyl , substituted aminosulfonyl , carboxy, alkoxycarbonyl, cycloalkyloxycarbonyl, aryloxycarbonyl,
  • R 2 and R 3 or R 3 and R 4 together with the carbons they are attached to may form a substituted or unsubstituted ring, which may be aromatic or non-aromatic and may include one or more heteroatoms in the ring and may be fused with an aromatic or aliphatic ring; and
  • R 10 and R 11 are independently selected from the groups consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl , arylalkyl, aryl, heteroaryl, acyl, arylacyl, heteroarylacyl , sulfonyl, aminosulfonyl , substituted
  • aryloxycarbonyl carbamoyl and substituted carbamoyl, provided that R 10 and R 11 can't both be hydrogen, wherein said pharmaceutical composition is suitable for human or animal administration.
  • the present invention further provides a
  • composition comprising a pharmaceutically
  • the present invention further provides a
  • composition comprising a pharmaceutically
  • the present invention also provides a compound having the following general Formula II or a pharmaceutically
  • X is selected from the groups consisting of 0, S or N-R' , wherein R' is selected from the groups consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl , arylalkyl, aryl, heteroaryl, acyl, arylacyl, heteroarylacyl , sulfonyl, aminosulfonyl , substituted aminosulfonyl ,
  • alkoxycarbonyl cycloalkyloxycarbonyl , aryloxycarbonyl ,
  • R 2 is selected from the groups consisting of hydrogen, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, arylalkyl, aryl, heteroaryl, hydroxy, alkyloxy, aryloxy, heteroaryloxy, acyloxy, arylacyloxy, heteroarylacyloxy, alkylsulfonyloxy,
  • arylsulfonyloxy thio, alkylthio, arylthio, amino, alkylamino, dialkylamino, cycloalkylamino, heterocycloalkylamino, arylamino, heteroarylamino, acylamino, arylacylamino, heteroarylacylamino, alkylsulfonylamino, arylsulfonylamino, acyl, arylacyl, amino, alkylamino, dialkylamino, cycloalkylamino, heterocycloalkylamino, arylamino, heteroarylamino, acylamino, arylacylamino, heteroarylacylamino, alkylsulfonylamino, arylsulfonylamino, acyl, arylacyl,
  • heteroarylacyl alkylsulfinyl , arylsulfinyl , alkylsulfonyl , arylsulfonyl , aminosulfonyl , substituted aminosulfonyl , carboxy, alkoxycarbonyl, cycloalkyloxycarbonyl, aryloxycarbonyl,
  • R 5 and R 6 or R 7 together with the nitrogen atoms they are attached to, along with the carbon of G
  • R 5 and R 8 or R 9 together with the nitrogen atoms they are attached to, along with the carbon of G and two carbons of the X-containing 5-membered ring, may form a substituted or unsubstituted ring, which may be fused with an aromatic or aliphatic ring;
  • R 6 , R 7 , R 8 , and R 9 are independently selected from the groups consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, arylalkyl, aryl, heteroaryl, acyl, arylacyl, heteroarylacyl, sulfonyl, aminosulfonyl , substituted
  • R 6 or R' and R 5 together with the nitrogen atoms they are attached to, along with the carbon of G, or R 8 or R 9 and R 5 , together with the nitrogen atoms they are attached to, along with the carbon of G and two carbons of the X-containing 5-membered ring, or R 6 or R 7 and R 8 or R 9 , together with the nitrogen atoms they are attached to, along with the carbon or sulfur of G and two carbons of the X-containing 5-membered ring, or R 6 and R 7 , together with the nitrogen atom they are attached to, or R 8 and R 9 , together with the nitrogen atom they are attached to, may form a substituted or unsubstituted ring, which may be fused with an aromatic or aliphatic ring; and
  • a 7 or 8-membered ring which contains one or more heteroatoms selected from N, 0 and S, or a 4-membered ring which may
  • the ring may be substituted or unsubstituted, or fused with another ring, which may be aromatic or non-aromatic and may include one or more heteroatoms in the ring and may be fused with an aromatic or aliphatic ring.
  • the present invention also provides a compound having the following general Formula III or a pharmaceutically
  • X is selected from the groups consisting of: 0, S and N-R' , wherein R' is selected from the groups consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl , arylalkyl, aryl, heteroaryl, acyl, arylacyl, heteroarylacyl , sulfonyl, aminosulfonyl , substituted aminosulfonyl ,
  • alkoxycarbonyl cycloalkyloxycarbonyl , aryloxycarbonyl ,
  • R is selected from the group consisting of halogen, cyano, isocyano, nitro, amino, alkylamino, dialkylamino,
  • heteroarylamino acylamino, arylacylamino, heteroarylacylamino, alkylsulfonylamino, arylsulfonylamino, hydroxysulfonyl ,
  • aminosulfonyl substituted aminosulfonyl , acyl, arylacyl, heteroarylacyl , carboxy, alkoxycarbonyl, cycloalkyloxycarbonyl, aryloxycarbonyl, aminocarbonyl , and substituted aminocarbonyl;
  • B, D, and E are independently N or C-R 2 , C-R 3 and C-R 4 , respectively, wherein R 2 , R 3 and R 4 are independently selected from the group consisting of hydrogen, substituted or
  • heterocycloalkyl arylalkyl, aryl, heteroaryl, hydroxy
  • heteroarylacyloxy alkylsulfonyloxy, arylsulfonyloxy, thio, alkylthio, arylthio, amino, alkylamino, dialkylamino,
  • heteroarylamino acylamino, arylacylamino, heteroarylacylamino, alkylsulfonylamino, arylsulfonylamino, acyl, arylacyl,
  • heteroarylacyl alkylsulfinyl , arylsulfinyl , alkylsulfonyl , arylsulfonyl , aminosulfonyl , substituted aminosulfonyl , carboxy, alkoxycarbonyl, cycloalkyloxycarbonyl, aryloxycarbonyl,
  • R 2 and R 3 or R 3 and R 4 together with the carbons they are attached to may form a substituted or unsubstituted ring, which may be aromatic or non-aromatic and may include one or more heteroatoms in the ring and may be fused with an aromatic or aliphatic ring; and
  • R 10 and R 11 are independently selected from the groups consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl , arylalkyl, aryl, heteroaryl, acyl, arylacyl, heteroarylacyl , sulfonyl, aminosulfonyl , substituted
  • the present invention also provides a compound
  • the present invention further provides a method for the treatment of at least one type of a Dengue virus infection or disease associated therewith, comprising administering in a therapeutically effective amount to a mammal in need thereof, a compound of Formula I, II or III as indicated above or a
  • the present invention also provides a method for the treatment of at least one type of a Dengue infection or disease associated therewith, comprising administering in a
  • a compound or a pharmaceutically acceptable salt thereof wherein said compound is selected from the group consisting of: 3-amino- N- (4-bromophenyl) -6- (4-chlorophenyl) thieno [2, 3-b] pyridine-2- carboxamide; 3-amino-6- ( 3-methoxyphenyl ) -N- [4-
  • intermediate compounds used in the synthesis of the compounds of the present invention are selected from the group consisting of: tert-butyl (4E)-4- (hydroxymethylene) -5-oxoazepane-l-carboxylate; tert-butyl (3E) - 3- (hydroxymethylene) -4-oxoazepane-l-carboxylate; tert-butyl 3- cyano-2-thioxo-l , 2,5,6,8, 9-hexahydro-7H-pyrido [2, 3-d] azepine-7- carboxylate ; tert-butyl 3-cyano-2-thioxo-l , 2,5,7,8, 9-hexahydro- 6H-pyrido [3, 2-c] azepine- 6-carboxylate ; and 3-amino-7-tert- butyloxycarbonyl-6, 7,8, 9-tetrahydro-5H-l-thia-7 , 10-diaza-
  • the present invention further provides a method for the preparation of a mixture of tert-butyl (4E)-4- (hydroxymethylene) -5-oxoazepane-l-carboxylate and tert-butyl (3E) -3- (hydroxymethylene) -4-oxoazepane-l-carboxylate, said method comprising reacting tert-butyl 4-oxoazepane-l-carboxylate with N- [ tert-butoxy (dimethylamino) methyl ] -N, -dimethylamine .
  • the present invention also provides a method for the preparation of a mixture of tert-butyl 3-cyano-2-thioxo- 1,2,5,6,8, 9-hexahydro-7H-pyrido [2, 3-d] azepine-7-carboxylate and tert-butyl 3-cyano-2-thioxo-l , 2,5,7,8, 9-hexahydro- 6H-pyrido [3, 2- c] azepine- 6-carboxylate said method comprising reacting a mixture of tert-butyl (4E) -4- (hydroxymethylene) -5-oxoazepane-l- carboxylate and tert-butyl (3E) -3- (hydroxymethylene) -4- oxoazepane-l-carboxylate in the presence of 2- cyanoethanethioamide and piperidine acetate.
  • the present invention further provides a method for the preparation of 3-amino-7-tert-butyloxycarbonyl-6, 7, 8, 9- tetrahydro-5H-l-thia-7 , 10-diaza-cyclohepta [f ] indene-2-carboxylic acid ( 5-phenyl- [ 1 , 3 , 4 ] thiadiazol-2-yl ) -amide comprising reacting tert-butyl 3-cyano-2-thioxo-l , 2,5,6,8, 9-hexahydro-7H-pyrido [2, 3- d] azepine-7-carboxylate with 2-chloro-N- (5-phenyl-l, 3, 4- thiadiazol-2-yl) acetamide .
  • the present invention also provides a method for the preparation of 3-amino-6, 7, 8, 9-tetrahydro-5H-l-thia-7 , 10-diaza- cyclohepta [ f] indene-2-carboxylic acid (5-phenyl- [ 1 , 3 , 4 ] thiadiazol-2-yl ) -amide comprising reacting 3-amino-7- tert-butyloxycarbonyl-6, 7,8, 9-tetrahydro-5H-l-thia-7 , 10-diaza- cyclohepta [ f] indene-2-carboxylic acid (5-phenyl- [ 1 , 3 , 4 ] thiadiazol-2-yl ) -amide with HC1.
  • the present invention further provides a method for the preparation of 3-amino-6-tert-butyloxycarbonyl-6, 7, 8, 9- tetrahydro-5H-l-thia-6, 10-diaza-cyclohepta [f ] indene-2-carboxylic acid ( 5-phenyl- [ 1 , 3 , 4 ] thiadiazol-2-yl ) -amide comprising reacting tert-butyl 3-cyano-2-thioxo-l , 2,5,7,8, 9-hexahydro- 6H-pyrido [3, 2- c] azepine- 6-carboxylate with 2-chloro-N- (5-phenyl-l, 3, 4- thiadiazol-2-yl) acetamide .
  • the present invention also provides a method for the preparation of 3-amino-6, 7, 8, 9-tetrahydro-5H-l-thia-6, 10-diaza- cyclohepta [ f] indene-2-carboxylic acid (5-phenyl- [ 1 , 3 , 4 ] thiadiazol-2-yl ) -amide comprising reacting 3-amino-6- tert-butyloxycarbonyl-6, 7,8, 9-tetrahydro-5H-l-thia-6, 10-diaza- cyclohepta [ f] indene-2-carboxylic acid (5-phenyl- [ 1 , 3 , 4 ] thiadiazol-2-yl ) -amide with HC1. [000027] Other objects and advantages of the present invention will become apparent from the following description and appended claims .
  • X is selected from the groups consisting of 0, S and N-R' , wherein R' is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl , arylalkyl, aryl, heteroaryl, acyl, arylacyl, heteroarylacyl , sulfonyl, aminosulfonyl , substituted aminosulfonyl ,
  • alkoxycarbonyl cycloalkyloxycarbonyl , aryloxycarbonyl ,
  • R is selected from the group consisting of halogen, cyano, isocyano, nitro, amino, alkylamino, dialkylamino,
  • heteroarylamino acylamino, arylacylamino, heteroarylacylamino, alkylsulfonylamino, arylsulfonylamino, hydroxysulfonyl ,
  • R and R 1 together with the carbons they are attached to may form a substituted or unsubstituted ring; and A, B, D, and E are independently N or C-R , C-R , C-R and C-R 4 , respectively, wherein R 1 , R 2 , R 3 and R 4 are independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl,
  • heterocycloalkyl arylalkyl, aryl, heteroaryl, hydroxy
  • heteroarylacyloxy alkylsulfonyloxy, arylsulfonyloxy, thio, alkylthio, arylthio, amino, alkylamino, dialkylamino,
  • heteroarylamino acylamino, arylacylamino, heteroarylacylamino, alkylsulfonylamino, arylsulfonylamino, acyl, arylacyl,
  • heteroarylacyl alkylsulfinyl , arylsulfinyl , alkylsulfonyl , arylsulfonyl , aminosulfonyl , substituted aminosulfonyl , carboxy, alkoxycarbonyl , cycloalkyloxycarbonyl , aryloxycarbonyl ,
  • X is S; A is C-N3 ⁇ 4; B is C-R 2 and R 2 is fluoro substituted phenyl or B is C- H; D is a C-H; E is C-R 4 and R 4 is a thienyl or D is C-R 3 and E is C-R 4 , and R 3 and R 4 form a ring; and/or R is a substituted aminocarbonyl .
  • the compound of Formula I of the present invention is selected from the group consisting of: 3-amino- 6,7,8, 9-tetrahydro-5H-l-thia-10-aza-cyclohepta [f ] indene-2- carboxylic acid ( 5-phenyl- [ 1 , 3 , 4 ] thiadiazol-2-yl ) -amide ; 1- amino-5-methyl-6, 7,8, 9-tetrahydro-thieno [2, 3-c] isoquinoline-2- carboxylic acid (4-methyl-thiazol-2-yl) -amide; 3, 6-diamino-5- cyano-4-furan-2-yl-thieno [2, 3-b] pyridine-2-carboxylic acid (4- bromo-phenyl ) -amide; 3-amino- 6-ethyl-5 , 6, 7, 8-tetrahydro- thieno [2, 3-b] [ 1 , 6 ] naphthyridine-2-carbox
  • the compound of Formula I of the present invention is 3-amino-6, 7, 8, 9-tetrahydro-5H-l-thia-10- aza-cyclohepta [ f ] indene-2-carboxylic acid (5-phenyl- [1,3,4] thiadiazol-2-yl ) -amide .
  • X is selected from the groups consisting of 0, S or N-R' , wherein R' is selected from the groups consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl , arylalkyl, aryl, heteroaryl, acyl, arylacyl, heteroarylacyl , sulfonyl, aminosulfonyl , substituted aminosulfonyl , alkoxycarbonyl , cycloalkyloxycarbonyl , aryloxycarbonyl , carbamoyl and substituted carbamoyl;
  • R 2 is selected from the groups consisting of hydrogen, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl , arylalkyl, aryl, heteroaryl, hydroxy, alkyloxy, aryloxy, heteroaryloxy, acyloxy, arylacyloxy, heteroarylacyloxy, alkylsulfonyloxy,
  • arylsulfonyloxy thio, alkylthio, arylthio, amino, alkylamino, dialkylamino, cycloalkylamino, heterocycloalkylamino, arylamino, heteroarylamino, acylamino, arylacylamino, heteroarylacylamino, alkylsulfonylamino, arylsulfonylamino, acyl, arylacyl, amino, alkylamino, dialkylamino, cycloalkylamino, heterocycloalkylamino, arylamino, heteroarylamino, acylamino, arylacylamino, heteroarylacylamino, alkylsulfonylamino, arylsulfonylamino, acyl, arylacyl,
  • heteroarylacyl alkylsulfinyl , arylsulfinyl , alkylsulfonyl , arylsulfonyl , aminosulfonyl , substituted aminosulfonyl , carboxy, alkoxycarbonyl, cycloalkyloxycarbonyl, aryloxycarbonyl,
  • R 5 and R 6 or R 7 together with the nitrogen atoms they are attached to, along with the carbon of G, or R 5 and R 8 or R 9 , together with the nitrogen atoms they are attached to, along with the carbon of G and two carbons of the X-containing 5-membered ring, may form a substituted or unsubstituted ring, which may be fused with an aromatic or aliphatic ring;
  • R , R , R , and R are independently selected from the groups consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl , arylalkyl, aryl, heteroaryl, acyl, arylacyl, heteroarylacyl , sulfonyl, aminosulfonyl , substituted
  • R 6 or R' and R 5 together with the nitrogen atoms they are attached to, along with the carbon of G, or R 8 or R 9 and R 5 , together with the nitrogen atoms they are attached to, along with the carbon of G and two carbons of the X-containing 5-membered ring, or R 6 or R 7 and R 8 or R 9 , together with the nitrogen atoms they are attached to, along with the carbon or sulfur of G and two carbons of the X-containing 5-membered ring, or R 6 and R 7 , together with the nitrogen atom they are attached to, or R 8 and R 9 , together with the nitrogen atom they are attached to, may form a substituted or unsubstituted ring, which may be fused with an aromatic or aliphatic ring; and
  • a 7 or 8-membered ring which contains one or more heteroatoms selected from N, 0 and S, or a 4-membered ring which may
  • the compound of Formula II of the present invention is 3-amino-6, 7, 8, 9-tetrahydro-5H-l-thia-6, 10-diaza- cyclohepta [ f ] indene-2-carboxylic acid (5-phenyl- [1,3,4] thiadiazol-2-yl ) -amide .
  • the compound of Formula II of the present invention is 3-amino-6, 7, 8, 9-tetrahydro-5H-l-thia-7 , 10- diaza-cyclohepta [ f ] indene-2-carboxylic acid (5-phenyl- [1,3,4] thiadiazol-2-yl ) -amide .
  • X is selected from the groups consisting of: 0, S and N-R' , wherein R' is selected from the groups consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl , arylalkyl, aryl, heteroaryl, acyl, arylacyl, heteroarylacyl , sulfonyl, aminosulfonyl , substituted aminosulfonyl ,
  • alkoxycarbonyl cycloalkyloxycarbonyl , aryloxycarbonyl ,
  • R is selected from the group consisting of halogen, cyano, isocyano, nitro, amino, alkylamino, dialkylamino,
  • heteroarylamino acylamino, arylacylamino, heteroarylacylamino, alkylsulfonylamino, arylsulfonylamino, hydroxysulfonyl ,
  • aminosulfonyl substituted aminosulfonyl , acyl, arylacyl, heteroarylacyl , carboxy, alkoxycarbonyl, cycloalkyloxycarbonyl, aryloxycarbonyl, aminocarbonyl , and substituted aminocarbonyl;
  • B, D, and E are independently N or C-R 2 , C-R 3 and C-R 4 , respectively, wherein R 2 , R 3 and R 4 are independently selected from the group consisting of hydrogen, substituted or
  • heterocycloalkyl arylalkyl, aryl, heteroaryl, hydroxy
  • heteroarylacyloxy alkylsulfonyloxy, arylsulfonyloxy, thio, alkylthio, arylthio, amino, alkylamino, dialkylamino,
  • heteroarylamino acylamino, arylacylamino, heteroarylacylamino, alkylsulfonylamino, arylsulfonylamino, acyl, arylacyl,
  • heteroarylacyl alkylsulfinyl , arylsulfinyl , alkylsulfonyl , arylsulfonyl , aminosulfonyl , substituted aminosulfonyl , carboxy, alkoxycarbonyl, cycloalkyloxycarbonyl, aryloxycarbonyl,
  • R 2 and R 3 or R 3 and R 4 together with the carbons they are attached to may form a substituted or unsubstituted ring, which may be aromatic or non-aromatic and may include one or more heteroatoms in the ring and may be fused with an aromatic or aliphatic ring; and
  • R 10 and R 11 are independently selected from the groups consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl , arylalkyl, aryl, heteroaryl, acyl, arylacyl, heteroarylacyl , sulfonyl, aminosulfonyl , substituted
  • X is S; B is C-H; D is C-H; and E is C-R 4 and R 4 is a heteroaryl. Also preferably, D is C-R 3 and E is C-R 4 , and R 3 and R 4 form a ring. Again preferably, R is a substituted aminocarbonyl .
  • the compound of Formula III of the present invention is 3- [N- [3-amino- 6- (2-thienyl) thieno [2, 3-b] pyridine-2- carbonyl] -3- (trifluoromethyl) anilino] propanoic acid.
  • the compounds of the present invention also include compounds or a pharmaceutically acceptable salt thereof selected from the group consisting of: 3-amino-N-cyclohexyl-6, 7, 8, 9- tetrahydro-5H-cyclohepta [b] thieno [3, 2-e] pyridine-2-carboxamide; 3-amino-N-butyl-6, 7,8, 9-tetrahydro-5H-cyclohepta [b] thieno [3, 2- e] pyridine-2-carboxamide; 3-amino-N- (tert-butyl) -6,7,8,9- tetrahydro-5H-cyclohepta [b] thieno [3, 2-e] pyridine-2-carboxamide; 3-amino- 6-methyl-N- (5-phenyl-l, 3, 4-thiadiazol-2-yl) thieno [2, 3- b] pyridine-2-carboxamide; 3-amino-5-methyl-N- (5-phenyl-l, 3,
  • the compounds of the present invention also include a compound or a pharmaceutically acceptable salt thereof, wherein said compound is selected from the group consisting of: 3-amino- N- (4-bromophenyl) -6- (4-chlorophenyl) thieno [2, 3-b] pyridine-2- carboxamide; 3-amino-6- (3-methoxyphenyl) -N- [4-
  • said compound is 3-amino-N- (4- bromophenyl) -6- (4-chlorophenyl) thieno [2, 3-b] pyridine-2- carboxamide or 3-amino-6- ( 3-methoxyphenyl ) -N- [4- ( trifluoromethoxy) phenyl] thieno [2, 3-b] pyridine-2-carboxamide .
  • the method of the present invention is for the treatment of at least one type of a Dengue virus infection or disease associated therewith (each type of Dengue virus
  • the mammal is a human and the viral infection is a flavivirus infection. More preferably, the flavivirus is selected from the group consisting of Dengue virus, West Nile virus, yellow fever virus, Japanese
  • the flavivirus is a Dengue virus selected from the group consisting of DEN- 1 , DEN-2, DEN-3, and DEN-4.
  • the viral infection is associated with a condition selected from the group consisting of Dengue fever, Yellow fever, West Nile, St. Louis encephalitis, Hepatitis C, Murray Valley encephalitis, and Japanese encephalitis. Most preferably, the viral infection is associated with Dengue fever wherein said Dengue fever is selected from the group consisting of classical dengue fever and dengue hemorrhagic fever.
  • the method of the present invention may also comprise co-administration of: a) other antivirals; b) vaccines; and/or c) interferons or pegylated interferons.
  • the present invention also provides for methods of synthesis of compounds of the present invention, in particular 3-amino-6, 7,8, 9-tetrahydro-5H-l-thia-7 , 10-diaza- cyclohepta [ f ] indene-2-carboxylic acid (5-phenyl-
  • Novel Intermediates in the synthesis of the compounds of the present invention include but are not limited to each of tert-butyl (4E) -4- (hydroxymethylene) -5-oxoazepane-l-carboxylate; tert-butyl (3E) -3- (hydroxymethylene) -4-oxoazepane-l-carboxylate; tert-butyl 3-cyano-2-thioxo-l , 2,5,6,8, 9-hexahydro-7H-pyrido [2, 3- d] azepine-7-carboxylate; tert-butyl 3-cyano-2-thioxo- 1,2,5,7,8, 9-hexahydro- 6H-pyrido [3, 2-c] azepine- 6-carboxylate ; and 3-amino-7-tert-butyloxycarbonyl-6, 7,8, 9-tetrahydro-5H-l-thia-
  • patient or “subject” is meant to include any mammal.
  • a “mammal”, for purposes of treatment, refers to any animal classified as a mammal, including but not limited to, humans, experimental animals including rats, mice, and guinea pigs, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, cows, and the like.
  • Efficacy refers to the effectiveness of a particular treatment regime. Efficacy can be measured based on change of the course of the disease in
  • the terms “treating”, “treatment”, and the like are used herein to refer to obtaining a desired pharmacological and physiological effect.
  • the effect may be prophylactic in terms of preventing or partially preventing a disease, symptom, or condition thereof and/or may be therapeutic in terms of a partial or complete cure of a disease, condition, symptom, or adverse effect attributed to the disease.
  • treatment covers any treatment of a disease in a mammal, such as a human, and includes: (a) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it, i.e., causing the clinical symptoms of the disease not to develop in a subject that may be predisposed to the disease but does not yet
  • pathological inflammation over long periods of time and/or are such caused by the physiological responses to inappropriate inflammation present in a biological system over long periods of time are also contemplated.
  • acyl refers to the groups H-C(O)-, alkyl-C(O)-, substituted alkyl-C(O)-, alkenyl-C (0) - , substituted alkenyl-C (0) - , alkynyl-C (0) - , substituted alkynyl-C (0) - ,
  • cycloalkyl-C (0) - substituted cycloalkyl-C (0) - , aryl-C(O)-, substituted aryl-C(O)-, heteroaryl-C (0) - , substituted
  • heterocyclic-C (0) wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted
  • heterocyclic are as defined herein.
  • Alkylamino refers to the group -NRR where each R is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl,
  • alkenyl refers to alkenyl group preferably having from 2 to 10 carbon atoms and more preferably 2 to 6 carbon atoms and having at least 1 and preferably from 1-2 sites of alkenyl unsaturation .
  • Alkoxy refers to the group “alkyl-O-" which
  • Alkyl refers to linear or branched alkyl groups having from 1 to 10 carbon atoms, alternatively 1 to 6 carbon atoms. This term is exemplified by groups such as methyl, t- butyl, n-heptyl, octyl and the like.
  • Aryl or “Ar” refers to an unsaturated aromatic carbocyclic group of from 6 to 14 carbon atoms having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl) which condensed rings may or may not be aromatic
  • Substituted aryl refers to aryl groups which are substituted with from 1 to 3 substituents selected from the group consisting of hydroxy, acyl, acylamino, thiocarbonylamino, acyloxy, alkyl, substituted alkyl, alkoxy, substituted alkoxy, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amidino, alkylamidino, thioamidino, amino, aminoacyl,
  • cycloalkoxy substituted cycloalkoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, carboxyl, carboxylalkyl , carboxyl-substituted alkyl, carboxyl- cycloalkyl, carboxyl-substituted cycloalkyl, carboxylaryl , carboxyl-substituted aryl, carboxylheteroaryl , carboxyl- substituted heteroaryl, carboxylheterocyclic, carboxyl- substituted heterocyclic, carboxylamido, cyano, thiol,
  • thiocycloalkyl substituted thiocycloalkyl , thioheterocyclic, substituted thioheterocyclic, cycloalkyl, substituted
  • heteroaryl substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkoxy, substituted cycloalkoxy,
  • heteroaryloxy substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, oxycarbonylamino
  • heterocyclic -S (0) 2 _ substituted heterocyclic, -OS (0) 2 -alkyl , - OS (0) 2 _ substituted alkyl, -OS (0) 2 _ aryl , -OS (0) 2 _ substiruted aryl, -OS (0) 2-heteroaryl , -OS (0) 2 _ substituted heteroaryl, -0S(0)2 _ heterocyclic, -OS (0) 2 _ substituted heterocyclic, -0S(0)2 _ NRR where R is hydrogen or alkyl, -NRS (0) 2-alkyl, -NRS (0) 2 -substituted alkyl, -NRS (0) 2 -aryl , -NRS (0) 2 -substituted aryl, -NRS(0) 2 - heteroaryl, -NRS (0) 2 _ substituted heteroaryl, -NRS(0)2 _ NRR where R is hydrogen or alkyl, -
  • heterocyclic -NRS (0) 2 -substituted heterocyclic, -NRS(0) 2 -NR- alkyl, -NRS (0) 2 -NR-substituted alkyl, -NRS (0) 2 -NR-aryl , -NRS(0) 2 - NR-substiruted aryl, -NRS (0) 2 -NR-heteroaryl , -NRS(0) 2 -NR- substituted heteroaryl, -NRS (0) 2 -NR-heterocyclic, -NRS(0) 2 -NR- substiruted heterocyclic where R is hydrogen or alkyl, mono- and di-alkylamino, mono- and di- (substituted alkyl) amino, mono- and di-arylamino, mono- and di-substituted arylamino, mono- and di- heteroarylamino, mono- and di-substituted heteroarylamino, mono- and di-
  • heterocyclic and amino groups on the substituted aryl blocked by conventional blocking groups such as Boc, Cbz, formyl, and the like or substituted with -S0 2 NRR where R is hydrogen or alkyl.
  • Cycloalkyl refers to cyclic alkyl groups of from 3 to 8 carbon atoms having a single cyclic ring including, by way of example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl and the like. Excluded from this definition are multi-ring alkyl groups such as adamantanyl, etc.
  • Halo or "halogen” refers to fluoro, chloro, bromo and iodo.
  • Heteroaryl refers to an aromatic carbocyclic group of from 2 to 10 carbon atoms and 1 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur within the ring or oxides thereof.
  • Such heteroaryl groups can have a single ring (e.g., pyridyl or furyl) or multiple condensed rings
  • indolizinyl or benzothienyl wherein one or more of the condensed rings may or may not be aromatic provided that the point of attachment is through an aromatic ring atom.
  • heteroaryl having two nitrogen atoms in the heteroaryl, ring refers to a heteroaryl group having two, and only two, nitrogen atoms in the heteroaryl ring and optionally containing 1 or 2 other
  • heteroatoms in the heteroaryl ring such as oxygen or sulfur.
  • Substituted heteroaryl refers to heteroaryl groups which are substituted with from 1 to 3 substituents selected from the group consisting of hydroxy, acyl, acylamino,
  • thiocarbonylamino acyloxy, alkyl, substituted alkyl, alkoxy, substituted alkoxy, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amidino, alkylamidino, thioamidino, amino, aminoacyl, aminocarbonyloxy, aminocarbonylamino,
  • heterocyclic -S (0) 2 _ substituted heterocyclic, -OS (0) 2 -alkyl , - OS (0) 2 _ substituted alkyl, -OS (0) 2 _ aryl , -OS (0) 2 _ substituted aryl, -OS (0) 2 -heteroaryl , -OS (0) 2 _ substituted heteroaryl, -0S(0) 2 _ heterocyclic, -OS (0) 2 _ substituted heterocyclic, -OSO 2 -NRR where R is hydrogen or alkyl, -NRS (0) 2 -alkyl , -NRS (0) 2 _ substituted alkyl, -NRS (0) 2 -aryl, -NRS (0) 2 -substituted aryl, -NRS (0) 2 -heteroaryl , - NRS (0) 2 -substituted heteroaryl, -NRS (0) 2 -heterocyclic, -
  • alkyl independently selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl,
  • heterocyclic and amino groups on the substituted aryl blocked by conventional blocking groups such as Boc, Cbz, formyl, and the like or substituted with -SO 2 NRR where R is hydrogen or alkyl.
  • Sulfonyl refers to the group -S(0) 2 R where R is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl,
  • substituted alkyl alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl,
  • heterocyclic and substituted heterocyclic are as defined herein.
  • “Pharmaceutically-acceptable carrier” means a carrier that is useful in preparing a pharmaceutical composition or formulation that is generally safe, non-toxic, and neither biologically nor otherwise undesirable, and includes a carrier that is acceptable for veterinary use as well as human
  • “Pharmaceutically-acceptable cation” refers to the cation of a pharmaceutically-acceptable salt.
  • “Pharmaceutically-acceptable salt” refers to salts which retain the biological effectiveness and properties of compounds which are not biologically or otherwise undesirable.
  • Pharmaceutically-acceptable salts refer to pharmaceutically- acceptable salts of the compounds, which salts are derived from a variety of organic and inorganic counter ions well known in the art and include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the molecule contains a basic functionality, salts of organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like.
  • Pharmaceutically-acceptable base addition salts can be prepared from inorganic and organic bases. Salts derived from inorganic bases include, by way of example only, sodium,
  • Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, such as alkyl amines, dialkyl amines, trialkyl amines, substituted alkyl amines, di (substituted alkyl) amines, tri (substituted alkyl) amines, alkenyl amines, dialkenyl amines, trialkenyl amines, substituted alkenyl amines, di (substituted alkenyl) amines, tri (substituted alkenyl) amines, cycloalkyl amines,
  • triheteroaryl amines heterocyclic amines, diheterocyclic amines, triheterocyclic amines, mixed di- and tri-amines where at least two of the substituents on the amine are different and are selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic, and the like. Also included are amines where the two or three substituents, together with the amino nitrogen, form a heterocyclic or heteroaryl group.
  • Suitable amines include, by way of example only, isopropylamine, trimethyl amine, diethyl amine, tri (iso- propyl) amine, tri (n-propyl) amine, ethanolamine, 2- dimethylaminoethanol , tromethamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine,
  • carboxylic acid derivatives would be useful, for example, carboxylic acid amides, including carboxamides , lower alkyl carboxamides , dialkyl carboxamides, and the like.
  • Salts derived from inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
  • Salts derived from organic acids include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, salicylic acid, and the like.
  • a compound may act as a pro-drug.
  • Pro-drug means any compound which releases an active parent drug in vivo when such pro-drug is administered to a mammalian subject.
  • Pro-drugs are prepared by modifying functional groups present in such a way that the modifications may be cleaved in vivo to release the parent compound.
  • Pro-drugs include compounds wherein a hydroxy, amino, or sulfhydryl group is bonded to any group that may be cleaved in vivo to regenerate the free hydroxyl, amino, or sulfhydryl group, respectively.
  • pro-drugs include, but are not limited to esters (e.g., acetate, formate, and benzoate derivatives), carbamates (e.g., N, -dimethylamino- carbonyl) of hydroxy functional groups, and the like. [000076] "Treating" or “treatment” of a disease includes:
  • a “therapeutically-effective amount” means the amount of a compound that, when administered to a mammal for treating a disease, is sufficient to effect such treatment for the disease.
  • the “therapeutically-effective amount” will vary depending on the compound, the disease, and its severity and the age, weight, etc., of the mammal to be treated.
  • composition refers to a composition intended and suitable for human or animal administration.
  • a composition containing a compound of the present invention dissolved in a solvent such as water, organic solvent, alcohol or DMSO for the intended purpose of in-vitro testing or for any type of testing outside of an animal or human body is not considered a pharmaceutical composition as defined herein.
  • compounds will be administered in a therapeutically-effective amount by any of the accepted modes of administration for these compounds.
  • the compounds can be administered by a variety of routes, including, but not limited to, oral, parenteral (e.g., subcutaneous, subdural, intravenous, intramuscular, intrathecal, intraperitoneal, intracerebral, intraarterial, or intralesional routes of administration) , topical, intranasal, localized (e.g., surgical application or surgical suppository), rectal, and pulmonary (e.g., aerosols, inhalation, or powder) . Accordingly, these compounds are effective as both injectable and oral compositions.
  • parenteral e.g., subcutaneous, subdural, intravenous, intramuscular, intrathecal, intraperitoneal, intracerebral, intraarterial, or intralesional routes of administration
  • topical e.g., intranasal
  • localized e.g., surgical application or surgical suppository
  • the actual amount of the compound i.e., the active ingredient, will depend on a number of factors, such as the severity of the disease, i.e., the condition or disease to be treated, age, and relative health of the subject, the potency of the compound used, the route and form of administration, and other factors .
  • Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD 5 o
  • the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD 5 o/ED 5 o.
  • the data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans.
  • the dosage of such compounds lies within a range of circulating concentrations that include the ED 5 o with little or no toxicity.
  • the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
  • the therapeutically-effective dose can be estimated initially from cell culture assays.
  • a dose may be formulated in animal models to achieve a circulating plasma concentration range which includes the IC 50 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture.
  • IC 50 i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms
  • levels in plasma may be measured, for example, by high performance liquid chromatography.
  • compositions are administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its
  • Amounts effective for this use will depend on the disease condition being treated as well as by the judgment of the attending clinician depending upon factors such as the severity of the inflammation, the age, weight, and general condition of the patient, and the like.
  • compositions administered to a patient are in the form of pharmaceutical compositions described supra. These compositions may be sterilized by conventional sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts.
  • the active compound is effective over a wide dosage range and is generally administered in a pharmaceutically- or therapeutically-effective amount. The therapeutic dosage of the compounds will vary according to, for example, the particular use for which the treatment is made, the manner of
  • the dose will typically be in the range of about 0.5 mg to about 100 mg per kilogram body weight.
  • Effective doses can be extrapolated from dose- response curves derived from in vitro or animal model test systems.
  • the clinician will administer the compound until a dosage is reached that achieves the desired effect.
  • compositions contain as the active ingredient one or more of the compounds above, associated with one or more pharmaceutically-acceptable carriers or excipients.
  • excipient employed is typically one suitable for administration to human subjects or other mammals.
  • the active ingredient is usually mixed with an excipient, diluted by an excipient, or enclosed within a carrier which can be in the form of a capsule, sachet, paper or other container.
  • a carrier which can be in the form of a capsule, sachet, paper or other container.
  • the excipient serves as a diluent, it can be a solid, semi ⁇ solid, or liquid material, which acts as a vehicle, carrier, or medium for the active ingredient.
  • compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium) , ointments
  • the active compound In preparing a formulation, it may be necessary to mill the active compound to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it ordinarily is milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size is normally adjusted by milling to provide a substantially uniform distribution in the formulation, e.g., about 40 mesh.
  • excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and methyl cellulose.
  • the formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates ; sweetening agents; and flavoring agents.
  • the compositions of the invention can be formulated so as to provide quick, sustained, or delayed-release of the active ingredient after administration to the patient by employing procedures known in the art.
  • unit dosage forms refers to physically-discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
  • the compound can be formulated for parenteral
  • a suitable inert carrier such as a sterile physiological saline solution.
  • the dose administered will be determined by route of administration.
  • intravenous formulation should possess certain qualities aside from being just a composition in which the therapeutic agent is soluble.
  • the formulation should promote the overall stability of the active ingredient ( s ) , also, the
  • manufacture of the formulation should be cost-effective. All of these factors ultimately determine the overall success and usefulness of an intravenous formulation.
  • solvents ethanol, glycerol, propylene glycol
  • stabilizers EDTA (ethylene diamine tetraacetic acid) , citric acid
  • antimicrobial agents include ethanol, glycerol, propylene glycol
  • EDTA ethylene diamine tetraacetic acid
  • preservatives benzyl alcohol, methyl paraben, propyl paraben; buffering agents: citric acid/sodium citrate, potassium hydrogen tartrate, sodium hydrogen tartrate, acetic acid/sodium acetate, maleic acid/sodium maleate, sodium hydrogen phthalate,
  • phosphoric acid/potassium dihydrogen phosphate phosphoric acid/disodium hydrogen phosphate
  • tonicity modifiers sodium chloride, mannitol, dextrose.
  • the presence of a buffer is necessary to maintain the aqueous pH in the range of from about 4 to about 8.
  • the buffer system is generally a mixture of a weak acid and a soluble salt thereof, e.g., sodium citrate/citric acid; or the monocation or dication salt of a dibasic acid, e.g., potassium hydrogen tartrate; sodium hydrogen tartrate, phosphoric acid/potassium dihydrogen phosphate, and phosphoric acid/disodium hydrogen phosphate .
  • the amount of buffer system used is dependent on (1) the desired pH; and (2) the amount of drug. Generally, the amount of buffer used is able to maintain a formulation pH in the range of 4 to 8. Generally, a 1:1 to 10:1 mole ratio of buffer (where the moles of buffer are taken as the combined moles of the buffer ingredients, e.g., sodium citrate and citric acid) to drug is used.
  • a useful buffer is sodium citrate/citric acid in the range of 5 to 50 mg per ml. sodium citrate to 1 to 15 mg per ml. citric acid, sufficient to maintain an aqueous pH of 4-6 of the composition .
  • the buffer agent may also be present to prevent the precipitation of the drug through soluble metal complex
  • the agent may act as a
  • an agent e.g., sodium chloride in an amount of about of 1-8 mg/ml, to adjust the tonicity to the same value of human blood may be required to avoid the swelling or shrinkage of erythrocytes upon
  • the tonicity of the formulation matches that of human blood which is in the range of 282 to 288 mOsm/kg, and in general is 285 mOsm/kg, which is equivalent to the osmotic pressure corresponding to a 0.9% solution of sodium chloride.
  • An intravenous formulation can be administered by direct intravenous injection, i.v. bolus, or can be administered by infusion by addition to an appropriate infusion solution such as 0.9% sodium chloride injection or other compatible infusion solution .
  • compositions are preferably formulated in a unit dosage form, each dosage containing from about 5 to about 100 mg, more usually about 10 to about 30 mg, of the active
  • unit dosage forms refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
  • the active compound is effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It will be understood, however, that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
  • the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention.
  • a solid preformulation composition containing a homogeneous mixture of a compound of the present invention.
  • the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
  • This solid preformulation is then subdivided into unit dosage forms of the type described above containing from, for example, 0.1 to about 2000 mg of the active ingredient.
  • the tablets or pills may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
  • the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
  • the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release.
  • enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
  • liquid forms in which the novel compositions may be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
  • compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically-acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
  • the liquid or solid compositions may contain suitable
  • compositions in pharmaceutically-acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device may be attached to a face masks tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered from devices which deliver the formulation in an appropriate manner.
  • the compounds can be administered in a sustained release form. Suitable examples of sustained-release
  • preparations include semipermeable matrices of solid hydrophobic polymers containing the compounds, which matrices are in the form of shaped articles, e.g., films, or microcapsules.
  • sustained-release matrices examples include polyesters, hydrogels (e.g., poly (2- hydroxyethyl-methacrylate) as described by Langer et al . , J. Biomed. Mater. Res. 15: 167-277 (1981) and Langer, Chem. Tech. 12: 98-105 (1982) or poly(vinyl alcohol)), polylactides (U.S. Patent No. 3,773,919), copolymers of L- glutamic acid and gamma ethyl-L-glutamate (Sidman et al . ,
  • LUPRON DEPOTTM i.e., injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate
  • EP 133, 988 poly-D- ( - ) -3-hydroxybutyric acid
  • the compounds can be administered in a sustained- release form, for example a depot injection, implant
  • Implants for sustained-release formulations are well-known in the art. Implants may be formulated as, including but not limited to, microspheres, slabs, with biodegradable or non-biodegradable polymers. For example, polymers of lactic acid and/or glycolic acid form an erodible polymer that is well- tolerated by the host.
  • Transdermal delivery devices may also be employed. Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds in
  • transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U.S. Patent No. 5,023,252, issued June 11, 1991, herein incorporated by reference. Such patches may be constructed for continuous, pulsatile, or on-demand delivery of pharmaceutical agents.
  • Direct techniques usually involve placement of a drug delivery catheter into the host's ventricular system to bypass the blood-brain barrier.
  • a drug delivery catheter into the host's ventricular system to bypass the blood-brain barrier.
  • One such implantable delivery system used for the transport of biological factors to specific anatomical regions of the body is described in U.S. Patent No. 5,011,472, which is herein incorporated by reference.
  • Indirect techniques usually involve formulating the compositions to provide for drug latentiation by the conversion of hydrophilic drugs into lipid-soluble drugs. Latentiation is generally achieved through blocking of the hydroxy, carbonyl, sulfate, and primary amine groups present on the drug to render the drug more lipid-soluble and amenable to transportation across the blood-brain barrier.
  • the delivery of hydrophilic drugs may be enhanced by intra-arterial infusion of hypertonic solutions which can transiently open the blood-brain barrier .
  • the compounds may be encapsulated, introduced into the lumen of liposomes, prepared as a colloid, or other conventional techniques may be employed which provide an extended serum half-life of the compounds.
  • a variety of methods are available for preparing liposomes, as described in, e.g., Szoka et al . , U.S. Patent Nos. 4,235,871, 4,501,728 and 4,837,028 each of which is incorporated herein by reference.
  • compositions are suitable for use in a variety of drug delivery systems. Suitable formulations for use in the present invention are found in Remington' s Pharmaceutical Sciences, Mace Publishing Company, Philadelphia, PA, 17th ed.
  • a tablet formula is prepared using the ingredients below :
  • Stearic acid 5.0 [0000116] The components are blended and compressed to form tablets, each weighing 240 mg.
  • the active mixture is mixed with the lactose and the mixture is added to a dry powder inhaling
  • Capsules each containing 40 mg of medicament, are made as follows:
  • magnesium stearate are blended, passed through a No . 20 mesh
  • Suppositories each containing 25 mg of active ingredient, are made as follows:
  • the active ingredient is passed through a No . 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2.0 g capacity and allowed to cool.
  • Purified water to 5.0 ml [0000126] The medicament, sucrose, and xanthan gum are blended, passed through a NO. 10 mesh U.S. sieve, and then mixed with a previously made solution of the microcrystalline cellulose and sodium carboxymethyl cellulose in water.
  • the sodium benzoate, flavor, and color are diluted with some of the water and added with stirring. Sufficient water is then added to produce the required volume.
  • Hard gelatin tablets each containing 15 mg of active ingredient, are made as follows:
  • magnesium stearate are blended, passed through a No . 20 mesh U.S. sieve, and filled into hard gelatin capsules in 560 mg
  • An intravenous formulation may be prepared as follows: Ingredient (mg/capsule)
  • Therapeutic compound compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle or similar sharp instrument .
  • a topical formulation may be prepared as follows:
  • the white soft paraffin is heated until molten.
  • the liquid paraffin and emulsifying wax are incorporated and stirred until dissolved.
  • the active ingredient is added and stirring is continued until dispersed.
  • the mixture is then cooled until solid .
  • Example 11 - Formulation 11 [0000133] An aerosol formulation may be prepared as follows: A solution of the candidate compound in 0.5% sodium
  • bicarbonate/saline (w/v) at a concentration of 30.0 mg/mL is prepared using the following procedure:
  • Example 12 Development of a high-throughput screening assay for measurement of dengue virus-induced cytopathic effect.
  • HTS dengue virus-induced cytopathic effect
  • the dengue virus CPE assay was used to evaluate compounds from the SIGA chemical library for those that inhibit dengue virus-induced CPE. Each evaluation run consisted of 48 96-well plates with 80 compounds per plate to generate 4,608 data points per run. At this throughput we are capable of evaluating 200,000 compounds in about 52 weeks. Compounds were dissolved in DMSO and diluted in medium such that the final concentration in each well was 5 ⁇ compound and 0.5% DMSO. The compounds were added robotically to the culture medium using the PerkinElmer MultiPROBE® II HT PLUS robotic system. Following compound addition, cultures were infected with dengue virus (DEN-2 strain New Guinea C) . After 5 days incubation, plates were processed and CPE quantified on a PerkinElmer EnVision II plate reader system.
  • ratio of signal of cell control wells (signal) to virus control wells (noise) was 5.0 ⁇ 1.2.
  • the well-to-well variability was determined for each individual plate and found to have a
  • Example 13 Determining Anti-Dengue-2 Activity of Compounds of the Invention : [0000139]
  • the assay described in Example 12 was the basis of a high-throughput screen for dengue virus inhibitors, against which a library of 210,000 compounds was tested.
  • Compounds that inhibited dengue virus induced CPE by at least 50% were further investigated for chemical tractability, potency, and
  • a chemically tractable compound is defined as one that is synthetically accessible using reasonable chemical methodology, and which possesses chemically stable functionalities and potential drug ⁇ like qualities. Hits that passed this medicinal chemistry filter were evaluated for their potency. Compound potency was
  • CC50 CC50/EC50
  • T.I. CC50/EC50
  • Vero cells in 12-well plates were infected with dengue-2 virus at a multiplicity of infection (MOI) of 0.1, treated with compound (or DMSO as a control), incubated at 37°C, harvested 48 hours post infection and titered on Vero cells as described above.
  • MOI multiplicity of infection
  • the EC 5 o was calculated through ExcelFit.
  • Compound 1 was identified as one of the most potent and selective compounds from within the pool of the initial quality hits, with activity against all four serotypes of dengue. Chemical analogs of this compound were obtained, and these analogs were tested as described in order to define the relationship between chemical structure and biological activity
  • Table 1 Compounds active against Dengue-2 Virus in Vero cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/US2013/073449 2012-12-07 2013-12-06 Thienopyridine derivatives for the treatment and prevention of dengue virus infections WO2014089378A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA2893318A CA2893318A1 (en) 2012-12-07 2013-12-06 Thienopyridine derivatives for the treatment and prevention of dengue virus infections
JP2015545858A JP2016501883A (ja) 2012-12-07 2013-12-06 デングウイルス感染症の治療及び予防のためのチエノピリジン誘導体
EP13859644.0A EP2928470A4 (en) 2012-12-07 2013-12-06 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/708,224 2012-12-07
US13/708,224 US20130129677A1 (en) 2009-02-27 2012-12-07 Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections

Publications (1)

Publication Number Publication Date
WO2014089378A1 true WO2014089378A1 (en) 2014-06-12

Family

ID=50884015

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/073449 WO2014089378A1 (en) 2012-12-07 2013-12-06 Thienopyridine derivatives for the treatment and prevention of dengue virus infections

Country Status (4)

Country Link
EP (1) EP2928470A4 (enrdf_load_stackoverflow)
JP (1) JP2016501883A (enrdf_load_stackoverflow)
CA (1) CA2893318A1 (enrdf_load_stackoverflow)
WO (1) WO2014089378A1 (enrdf_load_stackoverflow)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105418635A (zh) * 2015-12-25 2016-03-23 上海应用技术学院 一种噻吩并吡啶类医药中间体的合成方法
CN105769866A (zh) * 2016-03-31 2016-07-20 刘双彬 一种化合物在增加血小板浓度药物中的用途
CN105832734A (zh) * 2016-03-31 2016-08-10 刘双彬 一种化合物在增加血小板浓度药物中的用途
WO2017217439A1 (ja) * 2016-06-14 2017-12-21 国立大学法人東京大学 チエノ［２，３－ｂ］ピリジン誘導体およびキノリン誘導体ならびにそれらの使用
WO2019087129A1 (en) * 2017-11-03 2019-05-09 Universite De Montreal Compounds and use thereof in the expansion of stem cells and/or progenitor cells
WO2019234197A1 (en) * 2018-06-06 2019-12-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Thieno[2,3-b]pyridine derivatives as epac inhibitors and their pharmaceutical uses
CN111072463A (zh) * 2019-12-03 2020-04-28 辽宁凯莱英医药化学有限公司 一种4-乙氧基-1,1,1-三氟-3-丁烯-2-酮的连续化合成方法
WO2021035258A1 (en) * 2019-08-21 2021-02-25 The Scripps Research Institute Bicyclic agonists of stimulator of interferon genes sting
WO2021108999A1 (zh) * 2019-12-03 2021-06-10 辽宁凯莱英医药化学有限公司 一种4-乙氧基-1,1,1-三氟-3-丁烯-2-酮的连续化合成方法
WO2021250231A1 (en) * 2020-06-12 2021-12-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Thienopyridine derivatives for use in the treatment of coronavirus infection
CN116685317A (zh) * 2020-11-04 2023-09-01 杨森制药公司 固体制剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948916A (en) * 1994-09-22 1999-09-07 Rational Drug Design Laboratories Arylthiadiazole derivative and antiviral agent containing the same
US20100069371A1 (en) * 2003-07-24 2010-03-18 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
US20120022046A1 (en) * 2009-02-27 2012-01-26 Byrd Chelsea M Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections
US20130129677A1 (en) * 2009-02-27 2013-05-23 Siga Technologies, Inc. Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9717576D0 (en) * 1997-08-19 1997-10-22 Xenova Ltd Pharmaceutical compounds
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
AR048669A1 (es) * 2004-03-03 2006-05-17 Syngenta Ltd Derivados biciclicos de bisamida
SE0403171D0 (sv) * 2004-12-23 2004-12-23 Astrazeneca Ab New compounds
JP2006298909A (ja) * 2005-03-25 2006-11-02 Tanabe Seiyaku Co Ltd 医薬組成物
JP2009537551A (ja) * 2006-05-17 2009-10-29 アメリカ合衆国 ホルモン受容体を調節するためのピリミジン低分子量リガンド
US8785499B2 (en) * 2009-07-10 2014-07-22 University Of Maryland, Baltimore Targeting NAD biosynthesis in bacterial pathogens

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948916A (en) * 1994-09-22 1999-09-07 Rational Drug Design Laboratories Arylthiadiazole derivative and antiviral agent containing the same
US20100069371A1 (en) * 2003-07-24 2010-03-18 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
US20120022046A1 (en) * 2009-02-27 2012-01-26 Byrd Chelsea M Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections
US20130129677A1 (en) * 2009-02-27 2013-05-23 Siga Technologies, Inc. Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2928470A4 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105418635A (zh) * 2015-12-25 2016-03-23 上海应用技术学院 一种噻吩并吡啶类医药中间体的合成方法
CN105832734B (zh) * 2016-03-31 2018-05-04 南通江海港建设工程有限公司 一种化合物在增加血小板浓度药物中的用途
CN105769866A (zh) * 2016-03-31 2016-07-20 刘双彬 一种化合物在增加血小板浓度药物中的用途
CN105832734A (zh) * 2016-03-31 2016-08-10 刘双彬 一种化合物在增加血小板浓度药物中的用途
CN105769866B (zh) * 2016-03-31 2018-05-04 南通江海港建设工程有限公司 一种化合物在增加血小板浓度药物中的用途
US10689394B2 (en) 2016-06-14 2020-06-23 The University Of Tokyo Thieno[2,3-b]pyridine derivative, quinoline derivative, and use thereof
JPWO2017217439A1 (ja) * 2016-06-14 2019-04-11 国立大学法人 東京大学 チエノ［２，３−ｂ］ピリジン誘導体およびキノリン誘導体ならびにそれらの使用
WO2017217439A1 (ja) * 2016-06-14 2017-12-21 国立大学法人東京大学 チエノ［２，３－ｂ］ピリジン誘導体およびキノリン誘導体ならびにそれらの使用
JP7041877B2 (ja) 2016-06-14 2022-03-25 国立大学法人 東京大学 チエノ［２，３－ｂ］ピリジン誘導体およびキノリン誘導体ならびにそれらの使用
US11696928B2 (en) 2017-11-03 2023-07-11 Universite De Montreal Compounds and use thereof in the expansion of stem cells and/or progenitor cells
WO2019087129A1 (en) * 2017-11-03 2019-05-09 Universite De Montreal Compounds and use thereof in the expansion of stem cells and/or progenitor cells
CN111417640A (zh) * 2017-11-03 2020-07-14 蒙特利尔大学 化合物及其在干细胞和/或祖细胞扩增中的应用
CN111417640B (zh) * 2017-11-03 2024-04-05 蒙特利尔大学 化合物及其在干细胞和/或祖细胞扩增中的应用
WO2019234197A1 (en) * 2018-06-06 2019-12-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Thieno[2,3-b]pyridine derivatives as epac inhibitors and their pharmaceutical uses
CN112638382A (zh) * 2018-06-06 2021-04-09 国家医疗保健研究所 作为epac抑制剂的噻吩并[2，3-b]吡啶衍生物及其药物用途
CN112638382B (zh) * 2018-06-06 2024-10-18 国家医疗保健研究所 作为epac抑制剂的噻吩并[2，3-b]吡啶衍生物及其药物用途
WO2021035258A1 (en) * 2019-08-21 2021-02-25 The Scripps Research Institute Bicyclic agonists of stimulator of interferon genes sting
CN111072463A (zh) * 2019-12-03 2020-04-28 辽宁凯莱英医药化学有限公司 一种4-乙氧基-1,1,1-三氟-3-丁烯-2-酮的连续化合成方法
WO2021108999A1 (zh) * 2019-12-03 2021-06-10 辽宁凯莱英医药化学有限公司 一种4-乙氧基-1,1,1-三氟-3-丁烯-2-酮的连续化合成方法
WO2021250231A1 (en) * 2020-06-12 2021-12-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Thienopyridine derivatives for use in the treatment of coronavirus infection
CN116685317A (zh) * 2020-11-04 2023-09-01 杨森制药公司 固体制剂

Also Published As

Publication number Publication date
EP2928470A4 (en) 2015-12-16
CA2893318A1 (en) 2014-06-12
JP2016501883A (ja) 2016-01-21
EP2928470A1 (en) 2015-10-14

Similar Documents

Publication Publication Date Title
EP2400845B1 (en) Thienopyridine derivatives for the treatment and prevention of dengue virus infections
WO2014089378A1 (en) Thienopyridine derivatives for the treatment and prevention of dengue virus infections
US9029376B2 (en) Small molecule inhibitors for the treatment or prevention of dengue virus infection
US8993604B2 (en) Treatment and prevention of dengue virus infections
US20130129677A1 (en) Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections
US9353051B2 (en) Antiviral drugs for treatment or prevention of dengue infection
AU2010266570A1 (en) Treatment and prevention of Dengue virus infections
AU2015203873A1 (en) Thienopyridine derivatives for the treatment and prevention of dengue virus infections

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13859644

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2893318

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2015545858

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2013859644

Country of ref document: EP